🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#DYK? When detected early, the 5-year relative survival rate for localized #melanoma is approximately 99%. This #MelanomaMonday, check out this resource from Cleveland Clinic to learn how to complete a #SkinCancer self-exam to support #cancer detection: my.clevelandclinic.org/health/diagnos…

We announced our first quarter 2025 financial results and business highlights, including updates related to our ongoing research in #PancreaticCancer and non-small cell #LungCancer and corporate progress. For details, see our press release: ir.immuneering.com/news-releases/… $IMRX

This National #CancerResearch Month, we are recognizing the breakthroughs that have transformed cancer care while underscoring the ongoing need to improve support for #cancer patients. Learn more about our research here: immuneering.com/pipeline/

Our teams in Boston, NJ, and San Diego were proud to join more than 60,000 participants across the country for the #PanCANPurpleStride. To date, this event has helped raise over $19M to support the #PancreaticCancer community. Thank you PanCAN for organizing this impactful day.

Our CEO Ben Zeskind, PhD, sat down with Arundhati Parmar to discuss our research exploring the potential to develop more effective 𝘢𝘯𝘥 better tolerated therapies for #cancer patients by targeting the MAPK pathway. Watch the MedCity News podcast episode here: youtube.com/watch?v=N6SaVJ…

By cyclically inhibiting core signaling pathways in cancer cells to target MAPK driven tumors, we aim to advance a therapeutic approach with the potential to improve tolerability & expand indications compared to currently approved MEK inhibitor treatments: immuneering.com/pipeline/

During #SkinCancerAwarenessMonth, we recognize the vital work of The Skin Cancer Foundation 👒 and other advocates dedicated to raising awareness, sharing resources, and supporting individuals and families impacted by #SkinCancer, including #melanoma. Learn more: skincancer.org/get-involved/s…

We look forward to attending #BIO2025 to connect with peers across the #pharmaceutical and #biotech sectors. Interested in learning more about partnering opportunities? We welcome you to schedule a meeting with the $IMRX team through the BIO Partnering™ mobile app.

As #MemorialDay weekend approaches, AAD reminds us that UV exposure is the leading cause of #SkinCancer, including #melanoma. Skin cancer prevention starts with simple, consistent habits–explore key sun safety tips here: youtube.com/watch?v=xGKV8C…

We look forward to delivering a presentation at the Jefferies Global Healthcare Conference highlighting updates on our research as we seek to develop more effective 𝘢𝘯𝘥 better tolerated therapies for #cancer patients: bit.ly/4mDpL7J $IMRX #JefferiesHealthcare

In this episode of the Base to Base podcast, our CEO Ben Zeskind shares insights from our ongoing work to reimagine the potential of #cancer treatment as we advance an innovative approach to MEK inhibition. Tune in at the 27:25 mark to hear the discussion: rss.com/podcasts/base-…

#ASCO25 delivered powerful data, bold ideas, and meaningful conversations across #oncology. Our team leveraged the opportunity to exchange perspectives with peers who share our focus on driving meaningful change for people living with #cancer through scientific innovation. ASCO

Congratulations to our CSO Brett Hall, Ph.D., on being named a 2025 #LeaderOfInfluence in Life Sciences by @SDBJNews! This well-deserved recognition is a testament to Brett’s passion for helping cancer patients live longer and feel better: bit.ly/4mUe50s

This #CancerSurvivorsMonth, we are joining communities across the country in honoring the resilience of the 18.1 million #cancer survivors in the U.S. Explore personal stories of strength from cancer survivors and caregivers shared by National Cancer Institute here: bit.ly/3FQIwnH

Heading to #BIO2025 next week? We would welcome the chance to connect and discuss potential partnership opportunities – set up a meeting with our team through the BIO Partnering ™ mobile app.

During #PrideMonth, we celebrate the impact of LGBTQ+ professionals in #STEM whose contributions continue to drive innovation in #oncology research and patient care. At Immuneering, we value the important role that diverse perspectives play in shaping progress for patients.

#ICYMI Members of the $IMRX management team presented at the Jefferies Global Healthcare Conference where they highlighted key developments from our work to advance a therapeutic approach targeting MAPK-driven tumors in #cancer patients. Watch the replay: bit.ly/3ZQF9E4

We are pleased to report positive overall survival data from our ongoing Phase 2a trial evaluating our lead product candidate atebimetinib in first-line patients with #PancreaticCancer. Read our press release to learn more: ir.immuneering.com/news-releases/… $IMRX

We are focused on advancing innovation in MEK inhibition with the potential to help address key challenges associated with current standard of care treatments for MAPK-driven tumors, including issues related to tolerability. Learn more: immuneering.com/pipeline/

The positive overall survival data from our Phase 2a clinical trial with atebimetinib (IMM-1-104) in #PancreaticCancer represent a key development in our efforts to outpace #cancer to help patients outlive their disease. Learn more: endpoints.news/immuneering-re… Endpoints News Elizabeth Cairns